Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
Gilead Sciences (GILD) to Release Quarterly Earnings on Tuesday
Principal Financial Group Inc. Trims Holdings in Gilead Sciences, Inc. $GILD
Gilead Sciences Oncology Push Gains Traction With Trodelvy Keytruda Results
Gilead's Growing Oncology Role Reshapes The Investment Case For GILD
Nurix Therapeutics, Inc. (NRIX): A Bull Case Theory - Insider Monkey
Gilead Sciences, Inc. (GILD): A Bull Case Theory
Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer
TIGIT Inhibitors Market Poised for Strong Growth Through 2034, Driven by Expanding Immuno-Oncology Pipeline | DelveInsight
Best Pharmaceutical Stocks To Watch Today - February 1st - Markets Daily
Gilead Sciences (NASDAQ:GILD) Sets New 12-Month High on Analyst Upgrade
Gilead Sciences, Inc. $GILD Position Cut by TD Waterhouse Canada Inc.
Gilead Sciences, Inc. $GILD Stake Lessened by Convergence Investment Partners LLC
Truist Securities Raises Price Target on Gilead Sciences, Inc. (GILD) to $145, Keeps Buy Rating
Top Pharmaceutical Stocks To Add to Your Watchlist - January 31st - Markets Daily
Mediolanum International Funds Ltd Buys 9,971 Shares of Gilead Sciences, Inc. $GILD
Thrivent Financial for Lutherans Boosts Stake in Gilead Sciences, Inc. $GILD
AE Wealth Management LLC Buys 8,554 Shares of Gilead Sciences, Inc. $GILD
UBS Turns More Bullish on Gilead Sciences, Inc. (GILD) Amid Positive Pharma Sector Outlook
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $146.00 at Leerink Partners
10,471 Shares in Gilead Sciences, Inc. $GILD Acquired by Winnow Wealth LLC
Safety and biologic activity of a bispecific T cell receptor targeting HIV Gag in males living with HIV: a first-in-human trial
TD Cowen Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock - Markets Daily
Truist Financial Corp Has $34.45 Million Position in Gilead Sciences, Inc. $GILD - Zolmax
Gilead Sciences (NASDAQ:GILD) CEO Daniel Patrick O'day Sells 10,000 Shares of Stock - Markets Daily
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, TD Cowen Analyst Says - Stock Observer
Gilead Sciences, Inc. $GILD Holdings Lifted by Foundations Investment Advisors LLC
Patton Albertson Miller Group LLC Purchases Shares of 7,460 Gilead Sciences, Inc. $GILD - Daily Political
Insider Selling: Gilead Sciences (NASDAQ:GILD) CEO Sells 10,000 Shares of Stock
Chronic Hepatitis D Market Poised for Significant Growth During the Forecast Period (2025-2034) as Emerging Therapies Drive Optimism | DelveInsight
Wolfe Research Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price
Ruffer LLP Raises Stake in Gilead Sciences, Inc. $GILD
Mirae Asset Global Investments Co. Ltd. Grows Stake in Gilead Sciences, Inc. $GILD - Markets Daily
Gilead Sciences, Inc. $GILD is AustralianSuper Pty Ltd's 9th Largest Position
New York State Common Retirement Fund Sells 89,400 Shares of Gilead Sciences, Inc. $GILD - Stock Observer
Gilead Sciences (NASDAQ:GILD) Hits New 1-Year High Following Analyst Upgrade - Stock Observer
Federated Hermes Inc. Sells 324,814 Shares of Gilead Sciences, Inc. $GILD
Federated Hermes Inc. Has $294.80 Million Holdings in Gilead Sciences, Inc. $GILD - Daily Political
US Government Targets Major HIV and Arthritis Drugs for Medicare Price Negotiations in 2028, ETPharma
Gilead Sciences (GILD) Is Up 11.0% After Trodelvy Combo Outperforms Keytruda Chemo In Phase 3 Trial - Has The Bull Case Changed?
Gilead's Trodelvy Data Sparks Questions On Valuation And Oncology Growth
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $145.00
Citigroup Increases Gilead Sciences (NASDAQ:GILD) Price Target to $156.00
Gilead Sciences (NASDAQ:GILD) Reaches New 12-Month High Following Analyst Upgrade
Kornitzer Capital Management Inc. KS Reduces Holdings in Gilead Sciences, Inc. $GILD - Daily Political
Top Pharmaceutical Stocks To Keep An Eye On - January 26th - Markets Daily
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $155.00
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, UBS Group Analyst Says - Zolmax
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $150.00 at BMO Capital Markets
Gilead Sciences, Inc. $GILD Shares Sold by AEGON ASSET MANAGEMENT UK Plc
Gilead Sciences, Inc. $GILD is Sector Gamma AS's 9th Largest Position
AMF Tjanstepension AB Reduces Holdings in Gilead Sciences, Inc. $GILD
Medical Stocks Worth Watching - January 24th - Markets Daily
Mn Services Vermogensbeheer B.V. Acquires 8,500 Shares of Gilead Sciences, Inc. $GILD
Gilead Sciences, Inc. $GILD Shares Sold by Resona Asset Management Co. Ltd.
UniSuper Management Pty Ltd Has $62.38 Million Stake in Gilead Sciences, Inc. $GILD
Gilead Sciences, Inc. $GILD Shares Acquired by Envestnet Portfolio Solutions Inc.
UniSuper Management Pty Ltd Acquires 15,479 Shares of Gilead Sciences, Inc. $GILD - Stock Observer
Teacher Retirement System of Texas Sells 28,085 Shares of Gilead Sciences, Inc. $GILD - Stock Observer
Gilead Sciences (NASDAQ:GILD) Downgraded by Wall Street Zen to Buy
Best Medical Stocks To Keep An Eye On - January 23rd - Markets Daily
MOKAN Wealth Management Inc. Trims Position in Gilead Sciences, Inc. $GILD
Strs Ohio Purchases 24,284 Shares of Gilead Sciences, Inc. $GILD
Rakuten Investment Management Inc. Purchases New Shares in Gilead Sciences, Inc. $GILD - Markets Daily
Top Pharmaceutical Stocks To Watch Now - January 23rd - Daily Political
Grandfield & Dodd LLC Sells 20,655 Shares of Gilead Sciences, Inc. $GILD
Vest Financial LLC Acquires 6,019 Shares of Gilead Sciences, Inc. $GILD - Stock Observer
GILD: Extended HIV Franchise Strength Will Support Stronger Long-Term Earnings Power
CapWealth Advisors LLC Lowers Position in Gilead Sciences, Inc. $GILD
Gilead Sciences (NASDAQ:GILD) Director Jeffrey Bluestone Sells 5,000 Shares - Stock Observer
Analysts Conflicted on These Healthcare Names: Insulet (PODD) and Gilead Sciences (GILD) | Markets Insider
Jeffrey Bluestone Sells 5,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock
Gilead Sciences (NASDAQ:GILD) Reaches New 12-Month High After Analyst Upgrade - Markets Daily
Rothschild & Co Redburn Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price
Gilead Sciences (GILD) Valuation Check After Recent Share Price Softness
Gilead's Yeztugo Approval Highlights HIV Growth And Acquisition-Fueled Upside
Bernstein Remains a Buy on Gilead Sciences (GILD) | Markets Insider
Gilead Sciences, Inc. $GILD Shares Acquired by Wealth Enhancement Advisory Services LLC
Royal Bank Of Canada Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock
Triasima Portfolio Management inc. Grows Position in Gilead Sciences, Inc. $GILD - Daily Political
Tradewinds LLC. Takes $507,000 Position in Gilead Sciences, Inc. $GILD - Markets Daily
Mika Yamakawa Recognized With "Excellence In Healthcare Award" At Health 2.0 Conference, 2025 Edition
Gilead Sciences, Inc. (NASDAQ:GILD) Given Average Rating of "Moderate Buy" by Brokerages
Tradewinds LLC. Purchases New Position in Gilead Sciences, Inc. $GILD - Stock Observer
Allstate Corp Grows Position in Gilead Sciences, Inc. $GILD
Gilead Sciences, Inc. $GILD Shares Sold by QRG Capital Management Inc.
Andrew Dickinson Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock
Ritholtz Wealth Management Increases Stock Position in Gilead Sciences, Inc. $GILD - Markets Daily
Gilead Sciences, Inc. $GILD Shares Purchased by Ritholtz Wealth Management - Stock Observer
Morgan Stanley Cuts Gilead Sciences (NASDAQ:GILD) Price Target to $150.00 - Daily Political
Gilead news
Latest news
Show moreZelenskyy Expresses Doubts About Budapest as Venue for Ukraine Peace Talks
Europe Rallies Behind Ukraine Amid Trump Pressure, Eyes Frozen Russian Assets
Gold Price Surge Fueled by Fed Rate Cut Expectations and Economic Uncertainty
